Postmenopausal Breast Cancer

Studies find aromatase inhibitors (AIs) and bisphosphonates improve survival in postmenopausal breast cancer patients


Two new studies suggest that two different classes of drugs, aromatase inhibitors (AIs) and bisphosphonates, can each improve survival prospects for postmenopausal women with early breast cancer.

Anastrozole may be a new option for breast cancer prevention


Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced with the antihormone therapy anastrozole, according to the initial results of a double-blind, randomized, placebo-controlled trial presented at the 2013 San Antonio Breast Cancer Symposium.

Trastuzumab raises heart risk in older women with breast cancer

Heart failure is relatively common in older women undergoing breast cancer treatment, but trastuzumab therapy appears to raise the risk even more.

High mortality persists for black women with breast cancer

Black women have the highest death rate from breast cancer of all racial and ethnic groups, and are 40% more likely to die of the disease than are white women, according to a new report from the CDC.

Aspirin helps in some cancers

Aspirin helps in some cancers

Differences in the impact of aspirin in various forms of cancer are highlighted in two studies recently published in the oncology literature.

Treatment for breast cancer after menopause brings sexual difficulties


Women who receive aromatase inhibitors for breast cancer after menopause experience very high levels of sexual difficulties, including low interest, insufficient lubrication, and pain with intercourse, according to a recent study.

Radiation after lumpectomy might benefit older women after all

Most older women with early breast cancer are more likely to avoid mastectomy by following lumpectomy with radiation, contrary to current thinking.

Extra weight reduces effectiveness of estrogen-suppressing therapy

Overweight women with breast cancer were found to have more estrogen remaining after hormone-suppressing therapy than did women of healthy weight.

Shorter, stronger radiation course works in noninvasive breast cancer

Accelerated external-beam radiotherapy is a viable treatment option for ductal carcinoma in situ (DCIS), suggest recent study results.

Weight and inactivity impact cancer rates

Weight and inactivity impact cancer rates

Overall US cancer death rates have continued to decline since the early 1990s, but excess weight and lack of sufficient activity contribute to the increased incidence of many cancers.

Long-term cognitive effects seen with once-common breast chemotherapy regimen

Cognitive deficits subsequent to breast cancer chemotherapy using cyclophosphamide, methotrexate, and fluorouracil can be long-lasting.

Brachytherapy may be overused in breast cancer patients

Many women who underwent accelerated partial breast irradiation using brachytherapy were deemed cautionary or unsuitable for the procedure based on guidelines later issued by ASTRO.

Women saddled with multiple preoperative breast imaging visits

Preoperative breast-imaging claims on multiple dates have been increasing substantially since 1992, suggesting that the patient's time burden for such evaluation has also been increasing.

Older women should not rule out breast reconstruction

Age should not be a contraindication for breast reconstruction in elderly women, data from a retrospective chart review indicate.

Brachytherapy doubled risk for mastectomy, complications in older women

Although popular among older women with breast cancer, accelerated partial breast brachytherapy may be less effective and more toxic than standard whole breast irradiation in these patients.

Concurrent anastrozole/fulvestrant could be new first-line breast cancer treatment

Administering anastrozole (Arimidex) and fulvestrant (Faslodex) in combination rather than in sequence extended overall survival by 6 months in women with metastatic breast cancer, researchers reported at the CTRC-AACR San Antonio Breast Cancer Symposium.

Canadian guidelines state mammography is not needed before 50 years

The Canadian Task Force on Preventive Health Care is advising against routine mammography screening for women aged 40 to 49 and says to screen women aged 50 to 74 every 2 to 3 years.

Entinostat shows which users are most likely to have delayed breast cancer progression

Clinical outcome can be predicted shortly after administration of the HDAC inhibitor entinostat among women with metastatic breast cancer, according to the company that developed the agent.

Bisphosphonate therapy in breast cancer may help only older women

A large study has found that the routine use of zoledronic acid in the adjuvant management of breast cancer is not beneficial, but might extend survival in a subset of postmenopausal women.

Older women okay without hormone therapy for early breast cancer

Women 60 years and older who received no systemic adjuvant therapy for early-stage breast tumors were at no greater mortality risk than similarly aged women in the general population.

SEER may not see actual breast cancer radiation rates

A key health care database may not be accurately reflecting the use of radiation treatments after breast-conserving surgery among breast cancer patients, indicates a recent analysis.

Drug meets primary survival end point early in advanced breast cancer trial

A study of everolimus plus exemestane in metastatic breast cancer ended early, after an interim analysis revealed that the regimen significantly extended progression-free survival.

Risk factors are best determinants of optimal mammography intervals

Recommendations on how often a woman should undergo mammography screening should be personalized based on various risk factors, say researchers estimating the cost-effectiveness of mammography.

Many breast cancer patients have no family history of the disease

A significant portion of women who develop invasive breast cancer have no family history of the disease, indicating that other relevant factors should also be considered.

No disease-free survival benefit observed with zoledronic acid in stage II/III breast cancer

Adjuvant use of zoledronic acid did not improve disease-free survival in women with stage II/III breast cancer treated with adjuvant chemotherapy, concluded AZURE trial.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs